Monte-Serrano Juan, Villagrasa-Boli Pablo, Cruañes-Monferrer Joana, Arbués-Espinosa Patricia, Martínez-Cisneros Sara, García-Gil Miguel Fernando
Servicio de Dermatología y Venereología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España; Health Research Group GIIS100 of Health Research Institute IIS Aragón, Zaragoza, España.
Servicio de Dermatología y Venereología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España; Health Research Group GIIS100 of Health Research Institute IIS Aragón, Zaragoza, España.
Aten Primaria. 2022 Jun;54(6):102354. doi: 10.1016/j.aprim.2022.102354. Epub 2022 May 12.
To review and discuss the current evidence of the use of metformin as a therapeutic tool in frequent skin diseases.
Original article. Qualitative research. Narrative review.
Aragon and Murcia, Spain.
Resident Physicians. Dermatology and Primary Health Care.
A narrative review has been carried out using the PubMed bibliographic database, being the search date the 27th of January of 2022.
Metformin has proven to be effective in the treatment of inflammatory skin diseases such as acne, hidradenitis suppurativa, psoriasis and allergic contact dermatitis. It has also shown antitumor properties regarding basal cell carcinoma, squamous cell carcinoma and melanoma. Additionally, beneficial effects of adjuvant treatment with metformin have been described in patients with basal cell carcinoma receiving photodynamic therapy. In patients with endocrinology-related dermatosis such as hirsutism, acanthosis nigricans and eruptive xanthomas, treatment with metformin has demonstrated therapeutic effectiveness. Topical treatment with metformin has also been useful in the treatment of melasma. Finally, it has been proposed as a drug with anti-aging and wound-healing promoting properties. Severe adverse effects have not been observed for any of the previously described indications, being this a well-tolerated treatment.
Metformin is an effective and safe adjuvant in the therapeutic scheme of various inflammatory dermatoses, skin neoplasms, endocrinology-related dermatosis, melasma, skin aging and wound healing processes.
回顾并讨论二甲双胍作为常见皮肤病治疗工具的现有证据。
原创文章。定性研究。叙述性综述。
西班牙阿拉贡和穆尔西亚。
皮肤科和初级卫生保健住院医师。
使用PubMed文献数据库进行叙述性综述,检索日期为2022年1月27日。
二甲双胍已被证明对治疗痤疮、化脓性汗腺炎、银屑病和过敏性接触性皮炎等炎症性皮肤病有效。它在基底细胞癌、鳞状细胞癌和黑色素瘤方面也显示出抗肿瘤特性。此外,在接受光动力疗法的基底细胞癌患者中,已描述了二甲双胍辅助治疗的有益效果。在患有多毛症、黑棘皮病和发疹性黄瘤等内分泌相关皮肤病的患者中,二甲双胍治疗已显示出治疗效果。二甲双胍的局部治疗在黄褐斑的治疗中也很有用。最后,它已被提议作为一种具有抗衰老和促进伤口愈合特性的药物。对于上述任何适应症,均未观察到严重不良反应,这是一种耐受性良好的治疗方法。
二甲双胍在各种炎症性皮肤病、皮肤肿瘤、内分泌相关皮肤病、黄褐斑、皮肤老化和伤口愈合过程的治疗方案中是一种有效且安全的辅助药物。